CARA - Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive July, 19 2021 08:00 AM Cara Therapeutics Inc. CARA dropped due to a failed phase 2 trial in its second indication. Lead indication has a PDUFA on Aug 23, and it is unaffected by the other trial's failure. That makes the current drop attractive. For further details see: Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive